AAX Biotech Secures Investment From Trio Impact Invest
Biotechnology firm AAX Biotech has announced an investment from Trio Impact Invest. The funding will support the development and scaling of the company's antibody technology platforms.
Stockholm, Sweden – AAX Biotech, a company focused on technologies for antibody-based medicines, has secured an investment from Swedish venture capital firm Trio Impact Invest AB. The funding is intended to support the continued development and scaling of AAX Biotech's proprietary antibody technology platforms.
The company develops technologies such as Seqitope® and Opti-mAb®, designed to advance antibody discovery, optimization, and developability. AAX Biotech collaborates with partners across the industry to enhance antibody performance and support clinical development.
This investment follows a period of advancement for AAX Biotech, including the implementation of automation to improve platform scalability and new collaborations, such as one with Daiichi Sankyo. The capital from Trio Impact Invest will be used for platform advancement and to strengthen industry partnerships.
"This investment marks the next phase of platform development and expansion," said Daniel X Johansson, CEO and CSO of AAX Biotech. "With Trio Impact Invest’s support, we can scale our proprietary platforms, broaden their impact across antibody discovery and development, and strengthen collaborations with new and existing partners."
Trio Impact Invest focuses on early-stage, research-intensive deep tech companies with the potential for significant societal and commercial impact.